Early studies have shown constitutive activation of BTK in AML [33] and its role in AML-niche interaction in BM via SDF1/CXCR4 axis [34] or interaction with toll-like receptor 9 (TLR9) [35]. This evidence concerns the gene CXCL12 and acute myeloid leukemia.